BioMarin Pharmaceutical (BMRN) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and BioMarin published the results on November 2, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. BioMarin reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• BioMarin acquired Amicus Therapeutics on April 27, 2026, which added GALAFOLD and POMBILITI + OPFOLDA. Q3 2026 is their first full quarter in BioMarin's results, so the year-ago quarter has no revenue from them.
• Product figures are in millions as BioMarin rounds them in its release; royalty and other revenues are from the income statement.

Source: BioMarin Q3 2026 results, November 2, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How BioMarin splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• BioMarin's VOXZOGO revenue was $245 million in Q3 2026, up 12% from $218 million in Q3 2025, 24% of total revenue.
• BioMarin's Metabolic Conditions revenue was $744 million in Q3 2026, up 44% from $516 million in Q3 2025, 73% of total revenue.
• BioMarin's KUVAN revenue was $23.0 million in Q3 2026, down 4% from $24.0 million in Q3 2025, 2% of total revenue.
• BioMarin's ROCTAVIAN revenue was $1.0 million in Q3 2026, down 67% from $3.0 million in Q3 2025, under 1% of total revenue.
• BioMarin's Royalty and other revenues revenue was $11.6 million in Q3 2026, down 24% from $15.3 million in Q3 2025, 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

BioMarin's updated full-year 2026 table: Total Revenues $3,800 million to $3,900 million (was $3,875 million to $3,925 million), Metabolic Conditions $2,675 million to $2,750 million, VOXZOGO $975 million to $1,025 million, and Non-GAAP Diluted EPS $2.80 to $3.10 (was $4.90 to $5.10).

In its Q3 2026 release, BioMarin said:

“Revenue: Total Revenues, Metabolic Conditions, and VOXZOGO guidance updated to reflect uncertainty in the timing of multiple orders from a single international customer.”

“Non-GAAP Diluted EPS: BioMarin expects the Alesta acquisition and BMN 450 license agreement to result in total pre-tax charges of approximately $320 million and $83 million, respectively, for the full year 2026, consisting of the acquired IPR&D charges and ongoing operating expenses, representing an unfavorable impact of approximately $1.55 and $0.32, respectively, to both GAAP Diluted EPS and Non-GAAP Diluted EPS for the full year 2026.”

“Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding.”

“BioMarin continues to expect approximately $280 million of GAAP cost synergies (approximately $220 million on a Non-GAAP basis) to be fully realized in 2028.”

Source: BioMarin Q3 2026 release, Nov 2, 2026.

This is the company's own guidance as of Nov 2, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the BMRN forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenues and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for BioMarin's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 2, 2026

BioMarin's total revenues rose 32% to $1,025 million in Q3 2026, the first quarter above $1 billion. Metabolic Conditions products brought in $744 million, up 44%, and VOXZOGO for achondroplasia $245 million, up 12%. KUVAN added $23 million, ROCTAVIAN $1 million, and royalty and other revenues $11.6 million. (BioMarin Q3 2026 release, Nov 2, 2026)

Most of the growth came from the Amicus acquisition, completed on April 27, 2026: GALAFOLD for Fabry disease contributed $152 million and POMBILITI + OPFOLDA for Pompe disease $49 million. BioMarin also cited 18% growth in VIMIZIM from the timing of large international orders, while NAGLAZYME fell 11% on the timing of such orders. (BioMarin Q3 2026 release, Nov 2, 2026)

More than 75% of VOXZOGO revenue came from outside the U.S., and the number of children treated with VOXZOGO rose 17% from a year earlier, across 58 countries. BioMarin said a large international VOXZOGO order previously expected in the third quarter is now anticipated in the fourth. (BioMarin Q3 2026 release, Nov 2, 2026)

Of $956.5 million of net product revenues that BioMarin markets itself, the United States accounted for $352.0 million and Europe $364.6 million, with Latin America at $92.3 million and the rest of the world $147.6 million. ALDURAZYME, sold by Sanofi, added $56.6 million. BioMarin's three largest customers accounted for 34% of net product revenues, at 12%, 12% and 10%. (BioMarin Form 10-Q, Q3 2026, Nov 3, 2026)

BioMarin reported a GAAP diluted loss of $0.63 per share in Q3 2026 and Non-GAAP diluted EPS of $0.23. The Non-GAAP figure adds back $0.51 of intangible asset amortization, $0.28 of stock-based compensation, $0.24 of acquisition and restructuring-related costs and $0.09 of acquired inventory step-up, less a $0.26 tax effect. It does not exclude acquired IPR&D, so both measures carry that charge. (BioMarin Q3 2026 release, Nov 2, 2026)

Acquired IPR&D was $287.7 million in the quarter, which the 10-Q attributes to costs paid for BMN 440, the hypophosphatasia program from the Alesta acquisition. Interest expense rose to $55.6 million from $2.6 million because of the debt raised for Amicus, and intangible asset amortization rose to $99.5 million from $4.8 million. (BioMarin Form 10-Q, Q3 2026, Nov 3, 2026; BioMarin Q3 2026 release, Nov 2, 2026)

Total debt was $4,235.0 million at September 30, 2026, against $600.0 million at the end of 2025, including Term Loan B of $1,995.0 million and $850.0 million of 5.5% notes due 2034. The effective tax rate was 6.8%, and GAAP diluted shares were 193.6 million. (BioMarin Form 10-Q, Q3 2026, Nov 3, 2026; BioMarin Q3 2026 release, Nov 2, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

BioMarin gives full-year guidance in its release and cut it on November 2, 2026. Total revenue guidance moved to $3,800 million to $3,900 million from $3,875 million to $3,925 million, which BioMarin tied to uncertainty in the timing of multiple orders from a single international customer. VOXZOGO guidance is now $975 million to $1,025 million and Metabolic Conditions $2,675 million to $2,750 million. (BioMarin Q3 2026 release, Nov 2, 2026)

Non-GAAP diluted EPS guidance fell to $2.80 to $3.10 from $4.90 to $5.10. BioMarin expects the Alesta acquisition and the BMN 450 license to cost about $320 million and $83 million before tax in 2026, an unfavorable impact of about $1.55 and $0.32 per share. BioMarin does not give guidance for GAAP measures other than revenue. (BioMarin Q3 2026 release, Nov 2, 2026)

A consensus figure is the average of the models published by the analysts who cover BioMarin, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones BioMarin's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning BMRN is on is BMRN a buy or a sell?, what analysts expect next is on the BMRN forecast, and what the company does is on the BioMarin Pharmaceutical (BMRN) stock page.

Every number on this page can be traced to a document BioMarin published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.